Another new product recently was added to the R&D pipeline. That licensed drug treats gout, a fairly common affliction in China, and currently is in Phase II clinical trials. More international partnerships could emerge. We continue to estimate 2010 earnings will finish around $.65 a share. Next year $.75 a share remains a realistic target.
( Click on table to enlarge. )